TORONTO & SHANGHAI--(BUSINESS WIRE)-- #biotech--Cyclica, the partner of choice for data-driven drug discovery, and IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics with synthetic lethality approach, announce today that they have entered to a collaboration agreement on IMPACT Therapeutics’ differentiated targeted anti-cancer drug development. IMPACT Therapeutics will apply Cyclica’s Ligand Express platform to selectively unders
Business Wire Industry News
NEW YORK--(BUSINESS WIRE)-- #AI--Investable Universe announces Polar Futures, a provocative newsletter and podcast series exploring the Arctic’s geopolitical and economic issues.
Life Sciences Stakeholders Launch Collaboration to Advance Inclusion, Diversity, Equity and Accessibility (IDEA)
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Today seven founding member orgs announced the establishment of the Inclusive Life Sciences Collaboration.
VANCOUVER, British Columbia--(BUSINESS WIRE)--The 23rd Annual Life Sciences BC Awards, presented by FARRIS take place on September 23, 2021, celebrating the vibrant life sciences ecosystem in B.C.
PhenoTips Closes CAD $2.5M Funding Round Led by GreenSky Capital for Software to Transform Medical Genetics
TORONTO--(BUSINESS WIRE)-- #Funding--Genetics software startup PhenoTips® announced today that it has raised CAD $2.5 million in an oversubscribed seed fundraising round led by the GreenSky Accelerator Fund IV. This round includes the support of the Toronto Innovation Acceleration Partners, Thin Air Labs, Yorkville Partners, and angel investors including members of the GreenSky President’s Club. PhenoTips empowers healthcare providers to deliver precision medicine with the most complete and interoperable
Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform
BASEL, Switzerland & MONTRÉAL & AUSTIN, Texas--(BUSINESS WIRE)--Lonza and Triumvira Immunologics ("Triumvira") announced that the first patient has been dosed with Triumvira's investigational T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, in development for the treatment of HER2-overexpressing cancers. Triumvira's TAC01-HER2, which harnesses natural T cell activation, was manufactured on Lonza's proprietary Cocoon® Platform at C3i Center Inc in Montréal, Canada. The Coc
Biovectra Enhances Manufacturing Capacity and Flexibility with ABEC’s CSR® Large-Scale, Single-Use Microbial Fermentation Technology
BETHLEHEM, Pa. & CHARLOTTETOWN, Prince Edward Island--(BUSINESS WIRE)-- #CDMO--Biovectra Enhances Manufacturing Capacity and Flexibility with ABEC’s CSR® Large-Scale (up to 1,000L), Single-Use Microbial Fermentation Technology
Blade Therapeutics Announces Positive Data from Preclinical Drug-Drug Interaction Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis (IPF)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #Blade--Blade Therapeutics Announces Positive Data from Preclinical Drug-Drug Interaction Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor
Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™ for COVID-19 Patients
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics (TSX: APLI) Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™
Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition (the obese, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents) with mild symptoms of COVID-
Bioscience Association Manitoba Announces Report Identifying Risks to the Supply Chain of PPE In Manitoba
WINNIPEG, Manitoba--(BUSINESS WIRE)--Bioscience Association Manitoba (BAM) announced the publication of a new report designed to identify and understand the risks to the supply chain for Personal Protective Equipment (PPE) in Manitoba. Data was collected from relevant respondents in two interview phases to gain a better insight into supply chain management risk mitigation for PPE masks in Manitoba. The first phase focused on health care and academia, while the second phase focused on business a
TORONTO & DALLAS--(BUSINESS WIRE)-- #API--Medchart today announced the appointment of Kevin Callahan as vice president of product design and research.
Perimeter Medical Imaging AI Announces its Participation in Multiple Upcoming Industry Conferences and Events
TORONTO--(BUSINESS WIRE)---- $PINK.V #AI--Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced today that it will participate in the following upcoming industry events and conferences: Dr. Anthony Lucci from the Department of Breast Surgical Oncology, Division of Surgery at MD Anderson Cancer
Appili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus™ Viral Shedding Sub- Study for Mild-to-Moderate COVID-19 Patients
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus™ Viral Shedding Sub- Study for Mild-to-Moderate COVID-19 Patients
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #BCbiotech--Following a well-attended AGM, Life Sciences BC is pleased to announce new members to its Board of Directors, with thanks to those who are departing.
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--EUA of Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, at 2021 European Society of Medical Oncology Annual Meeting
TORONTO--(BUSINESS WIRE)--Alpha Cancer Technologies Inc. Presents New Data from ACT-903 at 2021 European Society of Medical Oncology Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces Health Canada approves its COVID-19 vaccine.
THUNDER BAY & TORONTO, Ontario--(BUSINESS WIRE)--Radialis Medical has submitted an FDA 510(k) premarket notification for its organ-targeted positron emission tomography (PET) system.
OTTAWA, Ontario--(BUSINESS WIRE)---- $BWXT--BWXT Medical and Bayer AG Enter into Agreement for the Development and Production of Actinium-225
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that new clinical data for zanidatamab, a HER2‑targeted bispecific antibody, demonstrate promising response rates and durability in first-line HER2-positive GEA. These data were presented today by lead study investigator, Geoffrey Ku, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center (MSK), at the ESMO
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will present at the following upcoming virtual investor conferences: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Monday, September 20, 2021 at 2:55 pm ET. (access here) Cantor Global Healthcare Conference on September 30, 2021 at 12:40 pm ET. (access here) In order to participate in the audio webcasts, interested p